Stock Research for LGND

LGND

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

LGND Stock Chart & Research Data

The LGND chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the LGND chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


LGND Due diligence Resources & Stock Charts

The LGND stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View LGND Detailed Price Forecast - CNN Money CNN View LGND Detailed Summary - Google Finance
Yahoo View LGND Detailed Summary - Yahoo! Finance Zacks View LGND Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View LGND Trends & Analysis - Trade-Ideas Barrons View LGND Major Holders - Barrons
NASDAQ View LGND Call Transcripts - NASDAQ Seeking View LGND Breaking News & Analysis - Seeking Alpha
Spotlight View LGND Annual Report - CompanySpotlight.com OTC Report View LGND OTC Short Report - OTCShortReport.com
TradeKing View LGND Fundamentals - TradeKing Charts View LGND SEC Filings - Bar Chart
WSJ View Historical Prices for LGND - The WSJ Morningstar View Performance/Total Return for LGND - Morningstar
MarketWatch View the Analyst Estimates for LGND - MarketWatch CNBC View the Earnings History for LGND - CNBC
StockMarketWatch View the LGND Earnings - StockMarketWatch MacroAxis View LGND Buy or Sell Recommendations - MacroAxis
Bullish View the LGND Bullish Patterns - American Bulls Short Pains View LGND Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View LGND Stock Mentions - StockTwits PennyStocks View LGND Stock Mentions - PennyStockTweets
Twitter View LGND Stock Mentions - Twitter Invest Hub View LGND Investment Forum News - Investor Hub
Yahoo View LGND Stock Mentions - Yahoo! Message Board Seeking Alpha View LGND Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for LGND - SECform4.com Insider Cow View Insider Transactions for LGND - Insider Cow
CNBC View LGND Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for LGND - OTC Markets
Yahoo View Insider Transactions for LGND - Yahoo! Finance NASDAQ View Institutional Holdings for LGND - NASDAQ


Stock Charts

FinViz View LGND Stock Insight & Charts - FinViz.com StockCharts View LGND Investment Charts - StockCharts.com
BarChart View LGND Stock Overview & Charts - BarChart Trading View View LGND User Generated Charts - Trading View




Latest Financial News for LGND


Ligand to Receive Milestone and Royalties as Result of FDA Approval of Sage Therapeutics’ ZULRESSO™ (brexanolone) Injection
Posted on Thursday March 21, 2019

Ligand Pharmaceuticals Incorporated (LGND) announced that it will receive a $3 million milestone payment as a result of the U.S. Food and Drug Administration’s (FDA) approval of Sage Therapeutics’ (SAGE) ZULRESSOTM (brexanolone) injection for the treatment of postpartum depression (PPD). ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth. PPD can affect women during pregnancy or after childbirth.


Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight
Posted on Tuesday March 19, 2019

Zacks.com featured highlights include: Catabasis, Ligand, Key, Carbonite and Second Sight


Rising P/E an Overlooked Criterion: 5 Top Stocks
Posted on Monday March 18, 2019

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratio.


Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $285,725 of Shares
Posted on Friday March 15, 2019

CEO of Ligand Pharmaceuticals Inc (NASDAQ:LGND) John L Higgins bought 2,500 shares of LGND on 03/13/2019 at an average price of $114.29 a share.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.